Inventor · disambiguated record
Hertzel Gerstein
Also filed as: GERSTEIN HERTZEL · GERSTEIN HERTZEL CHAIM
6 granted patents·16 pending applications·74 citations·filing 2003–2023
81Inventor score
Files withSANOFI AVENTIS DEUTSCHLAND8AVENTIS PHARMA GMBH6AVENTIS PHARMA INC2ROSSKAMP RALF2AVENTS PHARMA DEUTSCHLAND GMBH1
Top patents by PatentIndex Score
22 records- 0191US7977310B2Method for reducing cardiovascular morbidity and mortality in prediabetic patients and patients with type 2 diabetesAVENTIS PHARMA INC·Filed 2008·Granted Jul 12, 2011·19 cites·10 claims
- 0291US7405196B2Method for reducing cardiovascular morbidity and mortality in prediabetic patients and patients with type 2 diabetesAVENTIS PHARMA INC·Filed 2004·Granted Jul 29, 2008·43 cites·48 claims
- 0383US7368469B2Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular eventsSANOFI AVENTIS DEUTSCHLAND·Filed 2006·Granted May 6, 2008·12 cites·94 claims
- 0473US2024102093A1Growth Differentiation Factor 15 as Biomarker for MetforminSANOFI AVENTIS DEUTSCHLAND·Filed 2023·Application pending·0 cites
- 0566US11807905B2Growth differentiation factor 15 as biomarker for metforminSANOFI AVENTIS DEUTSCHLAND·Filed 2021·Granted Nov 7, 2023·0 cites·12 claims
- 0661US2009258919A1Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and / or congestive heart failureAVENTIS PHARMA GMBH·Filed 2009·Application pending·0 cites
- 0759US2010267798A1Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failureAVENTS PHARMA DEUTSCHLAND GMBH·Filed 2009·Application pending·0 cites
- 0858US2008125472A1Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failureSANOFI AVENTIS DEUTSCHLAND·Filed 2008·Application pending·0 cites
- 0957US10975434B2Growth differentiation factor 15 as biomarker for metforminSANOFI AVENTIS DEUTSCHLAND·Filed 2016·Granted Apr 13, 2021·0 cites·11 claims
- 1057US2008287403A1Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular eventsAVENTIS PHARMA GMBH·Filed 2008·Application pending·0 cites
- 1153US2006194868A1Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and /or congestive heart failureSANOFI AVENTIS DEUTSCHLAND·Filed 2006·Application pending·0 cites
- 1253US2013317047A1Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failureAVENTIS PHARMA GMBH·Filed 2012·Application pending·0 cites
- 1352US8809270B2Method for reducing cardiovascular morbidity and mortality in prediaetic patients and patients with type 2 diabetesROSSKAMP RALF·Filed 2012·Granted Aug 19, 2014·0 cites·2 claims
- 1452US2023088005A1Therapeutic uses of dulaglutideLILLY CO ELI·Filed 2021·Application pending·0 cites
- 1552US2005101658A1Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular eventsAVENTIS PHARMA GMBH·Filed 2004·Application pending·0 cites
- 1649US2011263619A1Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failureAVENTIS PHARMA GMBH·Filed 2010·Application pending·0 cites
- 1749US2004087645A1Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular eventsAVENTIS PHARMA GMBH·Filed 2003·Application pending·0 cites
- 1846US2011281793A1Method For Reducing Cardiovascular Morbidity And Mortality In Prediabetic Patients And Patients With Type 2 DiabetesROSSKAMP RALF·Filed 2011·Application pending·0 cites
- 1942US2008188538A1Methods of lowering glucose levelsGERSTEIN HERTZEL·Filed 2007·Application pending·0 cites
- 2040US2015065421A1Basal insulin therapySANOFI SA·Filed 2013·Application pending·0 cites
- 2129US2017102396A1New markers for the assessment of an increased risk for mortalitySANOFI AVENTIS DEUTSCHLAND·Filed 2015·Application pending·0 cites
- 2229US2017138961A1New markers for the assessment of the risk for development of a cardiovascular disorderSANOFI AVENTIS DEUTSCHLAND·Filed 2015·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →